|
EET-related genes
|
Non-cancerous tissue
|
Breast cancer tissue, no. of samples (%)
|
P value*
|
|---|
|
-
|
+
|
++
|
|---|
|
CYP2C8
|
-
|
28 (70%)
|
4 (10%)
|
4 (10%)
|
0.019
|
| |
+
|
0
|
0
|
2 (5%)
|
| |
++
|
0
|
0
|
2 (5%)
|
|
CYP2C9
|
-
|
12 (30%)
|
6 (15%)
|
4 (10%)
|
0.094
|
| |
+
|
4 (10%)
|
2 (5%)
|
6 (15%)
|
| |
++
|
0
|
2 (5%)
|
4 (10%)
|
|
CYP2J2
|
-
|
28 (70%)
|
6 (15%)
|
2 (5%)
|
0.019
|
| |
+
|
0
|
0
|
2 (5%)
|
| |
++
|
0
|
0
|
2 (5%)
|
|
sEH
|
-
|
10 (25%)
|
6 (15%)
|
0
|
0.034
|
| |
+
|
6 (15%)
|
2 (5%)
|
4 (10%)
|
| |
++
|
8 (20%)
|
2 (5%)
|
2 (5%)
|
- Sum of frequency and intensity scores: 0 or 1, negative (−); 2 or 3, moderately positive (+); 4 to 6, highly positive (++).
-
*Spearman correlation was used to analyze the correlation of clinicopathological variables and EET-related genes expression.
